About Histogenics (NASDAQ:HSGX)
Histogenics Corporation, a regenerative medicine company, focuses on developing and commercializing products in the musculoskeletal segment of the marketplace in the United States. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. It has an exclusive channel collaboration agreement with Intrexon Corporation for the development and commercialization of allogeneic genetically modified chondrocyte cell therapeutics for the treatment or repair of damaged articular hyaline cartilage in humans. Histogenics Corporation was founded in 2000 and is headquartered in Waltham, Massachusetts.
Industry, Sector and Symbol
Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:HSGX
CUSIPN/A
Phone781-547-7900
Debt
Debt-to-Equity RatioN/A
Current Ratio2.15%
Quick Ratio2.15%
Price-To-Earnings
Trailing P/E Ratio-2.76
Forward P/E Ratio-3.93
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value($0.46) per share
Price / Book-5.80
Profitability
EPS (Most Recent Fiscal Year)($0.98)
Net Income$-26,410,000.00
Net MarginsN/A
Return on Equity-658.91%
Return on Assets-131.87%
Miscellaneous
Employees45
Outstanding Shares28,690,000
Histogenics (NASDAQ:HSGX) Frequently Asked Questions
What is Histogenics' stock symbol?
Histogenics trades on the NASDAQ under the ticker symbol "HSGX."
How were Histogenics' earnings last quarter?
Histogenics Corp. (NASDAQ:HSGX) issued its quarterly earnings data on Thursday, March, 15th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.31) by $0.05. View Histogenics' Earnings History.
When is Histogenics' next earnings date?
What price target have analysts set for HSGX?
2 Wall Street analysts have issued twelve-month price targets for Histogenics' stock. Their forecasts range from $4.00 to $4.00. On average, they expect Histogenics' share price to reach $4.00 in the next twelve months. View Analyst Ratings for Histogenics.
Who are some of Histogenics' key competitors?
Who are Histogenics' key executives?
Histogenics' management team includes the folowing people:
- Mr. Adam D. Gridley, Chief Exec. Officer, Pres and Director (Age 46)
- Mr. Stephen R. Kennedy, COO & Exec. VP (Age 61)
- Mr. Jonathan I. Lieber, Chief Financial Officer (Age 48)
- Dr. Donald D. Haut Ph.D., Chief Bus. Officer
- Mr. Peter Hamilton, VP of Operations & Engineering (Age 54)
When did Histogenics IPO?
(HSGX) raised $60 million in an IPO on Wednesday, December 3rd 2014. The company issued 4,300,000 shares at a price of $13.00-$15.00 per share. Cowen and Company, Needham & Company and Canaccord Genuity acted as the underwriters for the IPO and BTIG was co-manager.
Has Histogenics been receiving favorable news coverage?
Headlines about HSGX stock have trended somewhat positive on Wednesday, Accern reports. The research firm identifies negative and positive press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Histogenics earned a news impact score of 0.18 on Accern's scale. They also gave news articles about the biotechnology company an impact score of 46.03 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
How do I buy shares of Histogenics?
Shares of HSGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Histogenics' stock price today?
One share of HSGX stock can currently be purchased for approximately $2.67.
How big of a company is Histogenics?
Histogenics has a market capitalization of $76.88 million. The biotechnology company earns $-26,410,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. Histogenics employs 45 workers across the globe.
How can I contact Histogenics?
Histogenics' mailing address is 830 WINTER STREET 3RD FLOOR, WALTHAM MA, 02451. The biotechnology company can be reached via phone at 781-547-7900 or via email at [email protected]
MarketBeat Community Rating for Histogenics (HSGX)
MarketBeat's community ratings are surveys of what our community members think about Histogenics and other stocks. Vote "Outperform" if you believe HSGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HSGX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Histogenics (NASDAQ:HSGX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
2 Wall Street analysts have issued ratings and price targets for Histogenics in the last 12 months. Their average twelve-month price target is $4.00, suggesting that the stock has a possible upside of 49.81%. The high price target for HSGX is $4.00 and the low price target for HSGX is $4.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $4.00 | $4.00 | $4.00 | $4.00 |
| Price Target Upside: | 49.81% upside | 36.05% upside | 94.17% upside | 123.11% upside |
Histogenics (NASDAQ:HSGX) Consensus Price Target History
Histogenics (NASDAQ:HSGX) Analyst Ratings History
Show:
(Data available from 4/25/2016 forward)
Histogenics (NASDAQ:HSGX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Histogenics (NASDAQ HSGX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 23.80%
Institutional Ownership Percentage: 42.96%
Histogenics (NASDAQ HSGX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 8/16/2017 | David N Gill | Director | Buy | 3,000 | $1.81 | $5,430.00 | 14,000 |  |
| 5/16/2017 | David N Gill | Director | Buy | 3,000 | $1.68 | $5,040.00 | 11,000 | |
| 12/15/2016 | David N Gill | Director | Buy | 3,000 | $1.65 | $4,950.00 | 8,000 | |
| 12/9/2016 | David N Gill | Director | Buy | 5,000 | $1.92 | $9,600.00 | 5,000 | |
| 12/2/2016 | Jonathan I Lieber | CFO | Buy | 5,000 | $1.95 | $9,750.00 | 5,000 | |
| 12/1/2016 | Adam Gridley | Insider | Buy | 5,000 | $2.01 | $10,050.00 | 5,000 | |
| 9/29/2016 | Split Rock Partners Ii, Lp | Major Shareholder | Buy | 276,801 | $2.25 | $622,802.25 | | |
(Data available from 1/1/2013 forward)
Histogenics (NASDAQ HSGX) News Headlines
| Source: |
|
Histogenics (NASDAQ:HSGX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Histogenics (NASDAQ:HSGX) Income Statement, Balance Sheet and Cash Flow Statement
Histogenics (NASDAQ HSGX) Stock Chart for Wednesday, April, 25, 2018
Loading chart…
